A director at Asa Gold & Precious Metals Ltd sold 13,355 shares at 70.600USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference, Virtual. Fireside discussion, February 25, 2026, 12:40 p.m. ET.TD...
FactSet Partners with Kepler Cheuvreux to Deliver GenAI-Activated AMR NORWALK, Conn., Feb. 10, 2026 (GLOBE NEWSWIRE) -- FactSet (NYSE:FDS | NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced a partnership with Kepler Cheuvreux to integrate Kepler Cheuvreux’s Aftermarket Research (AMR) into the FactSet platform. Enhanced by FactSet’s proprietary AI capabilities, Kepler Cheuvreux’s premium sell-side research advances FactSet’s commitment to delivering best-in-class AMR content across EMEA. “This partnership deepens our European equity covera...
FactSet Declares Dividend NORWALK, Conn., Feb. 05, 2026 (GLOBE NEWSWIRE) -- FactSet (NYSE:FDS | NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced that its Board of Directors approved a regular quarterly cash dividend of $1.10 per share. The cash dividend will be paid on March 19, 2026, to holders of record of FactSet’s common stock at the close of business on February 27, 2026. About FactSetFactSet (NYSE:FDS | NASDAQ:FDS) supercharges financial intelligence, offering enterprise data and information solutions that power our clients to max...
A director at Calix Inc sold 25,000 shares at 47.268USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
FactSet Launches AI Doc Ingest for Cobalt, Transforming Private Capital Data Collection with AI-Powered Automation By eliminating the need for client-side model training, private capital firms can now gain speed, accuracy, and data transparency with a new automated solution for ingesting portfolio company documents NORWALK, Conn., Feb. 04, 2026 (GLOBE NEWSWIRE) -- FactSet (NYSE:FDS | NASDAQ:FDS), a global financial digital platform and enterprise solutions provider, today announced the beta release of AI Doc Ingest for Cobalt, a powerful AI-powered solution designed to revolutionize por...
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Access to a live webcast of the event, as ...
TaskUs, Inc. (TASK - $11.11)AI Pivot Underway, We Think Up to the TASK; Mike Piccolo Initiating Coverage at OUTPERFORM with $15 Price Target. We are initiating coverage on TASK with an OUTPERFORM rating and a price target of $15 per share as we believe shares represent an attractive risk/reward opp
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.